Goat Milk
Phase 1Small molecule
Goat Milk is one of 46 small molecule programs targeting Allogeneic Hematopoietic Stem Cell Transplant Recipient. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
103 competitors in Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Amevive
AstellasPhase 3
Zinbryta
RochePhase 3
Cellcept
NovartisPhase 3
Cellcept
RochePhase 2
Pulmicort
SSalix
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Itacitinib
IncytePhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stem Cell Transplant1 trial
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Withdrawn·—·Phase 1·NCT03531281
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Goat Milk. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCity of Hope Medical Center